As regulatory delays continue to plague Regeneron’s Eylea franchise, quarterly sales for the eye disease medicine have dropped below $1 billion for the first time since the second quarter of 2018. More: Regeneron's quarterly sales of Eylea drop below B
read moreIn GSK’s first quarter with Luke Miels as CEO, the company’s flagship shingles vaccine Shingrix set a new quarterly sales record while its closely watched asthma launch Exdensur showed “early signals” of commercial progress despite a recent trial flop. More:
read moreNovartis CEO Vas Narasimhan says that Europe needs a “complete rethink” on how it prices its drugs, warning that the entrance of new pharmaceuticals into its markets could be delayed. More: Novartis CEO calls for 'complete rethink' of Europe's drug
read morePfizer now anticipates its Vyndamax sales to remain “relatively stable” from 2028 through mid-2031, it said. More: Pfizer’s victory in delaying Vyndamax generics is mixed bag for BridgeBio: analysts Source: fierce
read moreThe FDA has released briefing documents detailing its concerns for AstraZeneca’s cancer drugs camizestrant and Truqap ahead of an upcoming advisory committee meeting, the first such gathering in about nine months. More: FDA flags concerns for AstraZeneca's camizestrant, Truqap ahead
read moreThe FDA has told Amgen that it is proposing to withdraw the approval of the rare disease drug Tavneos. The FDA cited new information that indicates that data was “manipulated” to facilitate the approval of Tavneos. In addition, the FDA is
read more© 1994 - 2026 B.M. Pharmaceuticals